Phase I/II Study Exploring Safety and Efficacy of Apl-101 Plus Frontline Osimertinib in EGFR-mutated Metastatic Non-small Cell Lung Cancer

被引：0
|
作者：
Patel, B. [1 ]
Wu, N. [1 ]
Myles, S. [1 ]
Turlington, D. [1 ]
Yu, P. [2 ]
Saha, G. [2 ]
Rohatgi, A. [1 ]
Herzog, B. H. [1 ]
Ward, J. P. [1 ]
Baggstrom, M. Q. [1 ]
Waqar, S. N. [1 ]
Morgensztern, D. [1 ]
Govindan, R. [1 ]
Devarakonda, S. [1 ]
机构：
[1] Washington Univ, St Louis, MO 63110 USA
[2] Apollomics Inc, Foster City, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
MET TKI; EGFR TKI; Phase I/II;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.09-41
引用
收藏
页码：S350 / S350
页数：1
相关论文
共 50 条
  • [1] Safety of osimertinib in EGFR-mutated non-small cell lung cancer
    Mezquita, Laura
    Varga, Andreea
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1239 - 1248
  • [2] Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer
    Spagnuolo, Alessia
    Gridelli, Cesare
    EXPERT OPINION ON PHARMACOTHERAPY, 2025,
  • [3] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Alessandro Leonetti
    Sugandhi Sharma
    Roberta Minari
    Paola Perego
    Elisa Giovannetti
    Marcello Tiseo
    British Journal of Cancer, 2019, 121 : 725 - 737
  • [4] Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer
    Aredo, Jacqueline V.
    Urisman, Anatoly
    Gubens, Matthew A.
    Mulvey, Claire
    Allen, Greg M.
    Rotow, Julia K.
    Kerr, Daniel Lucas
    Chakrabarti, Turja
    Bacaltos, Bianca
    Gee, Megan
    Jones, Kirk
    Aisner, Dara L.
    Patil, Tejas
    Schenk, Erin Lynn
    Bivona, Trever G.
    Riess, Jonathan W.
    Coleman, Melissa
    Kratz, Johannes Ruediger
    Jablons, David
    Blakely, Collin M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Leonetti, Alessandro
    Sharma, Sugandhi
    Minari, Roberta
    Perego, Paola
    Giovannetti, Elisa
    Tiseo, Marcello
    BRITISH JOURNAL OF CANCER, 2019, 121 (09) : 725 - 737
  • [6] Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
    Aredo, Jacqueline, V
    Wakelee, Heather A.
    Neal, Joel W.
    Padda, Sukhmani K.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 30
  • [7] MERTK Activation Drives Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer
    Yan, D.
    Huelse, J.
    Parker, R.
    Wang, X.
    Frye, S.
    Earp, H. S.
    Deryckere, D.
    Graham, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1147 - S1147
  • [8] Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?
    Leonetti, Alessandro
    Facchinetti, Francesco
    Tiseo, Marcello
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
  • [9] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
    Fu, Kai
    Xie, Fachao
    Wang, Fang
    Fu, Liwu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [10] Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
    Kunimasa, Kei
    Kamada, Risa
    Oka, Toru
    Oboshi, Makiko
    Kimura, Madoka
    Inoue, Takako
    Tamiya, Motohiro
    Nishikawa, Tatsuya
    Yasui, Taku
    Shioyama, Wataru
    Nishino, Kazumi
    Imamura, Fumio
    Kumagai, Toru
    Fujita, Masashi
    JACC: CARDIOONCOLOGY, 2020, 2 (01): : 1 - 10
12345